Market research
ALPRE.PA Predilife S.A
PA EUR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 4M
- P/E ratio
- Not available
- Analyst target
- 20.92
- Beta
- Not available
Profile
Instrument facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- FR0010169920
- Market cap
- 4M
- P/E ratio
- Not available
- Analyst target
- 20.92
- Beta
- Not available
About
About Predilife S.A
Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. It provides breast cancer predictive assessment; and multi-pathology predictive assessment. The company also offers MammoRisk, a breast cancer prediction test based on the patient's individual risk; and DenSeeMammo, a breast density measurement software. Predilife S.A. was incorporated in 2004 and is headquartered in Villejuif, France.
Research context
Predilife S.A appears in PyInvesting’s Paris Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ALPRE.PA discussion.
5 years, 6 months ago
Predilife S.A is currently in a long term downtrend where the price is trading 4.9% below its 200 day moving average.
From a valuation standpoint, the stock is 66.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 92.2.
Based on the above factors, Predilife S.A gets an overall score of 1/5.